Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management and New Corporate Name
ACCESS PHARMACEUTICALS, INC., has signed an exclusive, global license agreement with Plasma Technologies LLC ("PlasmaTech") for the development and commercialization of its proprietary plasma fractionation process. Concurrently, the Company announced a new corporate management team and its intention to strategically refocus and rebrand the company as PlasmaTech Biopharmaceuticals, Inc., and its plans to pursue a national listing for its common shares.
View full press release